(IN BRIEF) Novartis will present new data from 27 abstracts at the 2025 American College of Rheumatology (ACR) Convergence, featuring late-breaking Phase III results from the NEPTUNUS-1 and NEPTUNUS-2 trials of ianalumab in Sjögren’s disease, which could become the first … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged ACR 2025, allergy, Angelika Jahreis, autoimmune diseases, Basel, biologics, biomarker research, CAR-T therapy, Cosentyx, Dermatology, EXPLORE44, Fortitude, HARBOR trial, ianalumab, immunology, NEPTUNUS trials, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Highlights Strong Immunology Pipeline with Positive Phase III Sjögren’s Results and CAR-T Data in Lupus at ACR 2025, Phase III data, psoriatic arthritis, rapcabtagene autoleucel, rheumatology, secukinumab, Sjögren’s disease, small molecules, systemic lupus erythematosus, YTB323
Company opens new pollen measurement station at its Drachten innovation center in the Netherlands AMSTERDAM, 26-Apr-2018 — /EuropaWire/ — This World Allergy Week (April 22 – 28) and World Asthma Day (May 1), Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in … Read the full press release
Posted in Healthcare, Netherlands, Technology
Tagged allergy, allergy symptoms, asthma, children’s asthma, pollen, Roy Jakobs, Royal Philips, WorldAllergyWeek, WorldAsthmaDay
Not for audiences in the US and Canada LONDON, 26-8-2015 — /EuropaWire/ — This week, epgonline.org, the website for healthcare professionals, welcomes the launch of a free symptomatic asthma Continuing Medical Education (CME) activity, available at epgonline.org/symptomatic-asthma/cme/. Accredited by the … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?